A 2 Part Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA), and to Characterize the Effect of Food on the Pharmacokinetics in Healthy Male and Female Subjects
Latest Information Update: 23 May 2024
At a glance
- Drugs SRP 001 (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors South Rampart Pharma
Most Recent Events
- 16 May 2024 According to a South Rampart Pharma media release, results from this trial published as a paper in Scientific Reports.
- 16 May 2024 Results presented in the South Rampart Pharma Media Release.
- 03 Jan 2024 According to a South Rampart Pharma media release, the company will present the latest clinical and scientific data on its lead clinical trail at Biotech Showcase 2024 on Tuesday, January 9.